SEST Study on Sitacretin® & Sitacretin Plus® – Real-World Diabetes Care

As part of its ongoing commitment to delivering effective and safe treatments for type 2 diabetes, Ibn Al Haytham Pharmaceutical Company proudly conducted the first Post-Marketing Surveillance (PMS) study on Sitagliptin (Sitacretin®) in Syria. The SEST study aimed to assess the efficacy, safety, and tolerability of Sitacretin® and Sitacretin Plus® in real-world clinical settings across the country.

The study included 711 patients between the ages of 20 and 75, followed over three months by 33 endocrinologists from various Syrian cities. The results demonstrated the following:

• An average reduction of 13.62% in HbA1c levels after 3 months.
• A 37.48% mean reduction in fasting blood glucose levels.
• Physicians rated efficacy as “Excellent to Good” in approximately 80% of patients.
• Safety and tolerability were evaluated as “Excellent to Good” in 75% of patients, with no serious adverse events or dropouts due to side effects.

These results reinforce the clinical confidence in Sitacretin as an effective and well-tolerated option aligned with everyday medical practice—offering high-quality therapeutic support for patients with diabetes across Syria.